Cancer Patients Clinical Trial
Official title:
Effect of Group Led Creative Writing on Mood in Cancer Patients
Verified date | October 2020 |
Source | Milton S. Hershey Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this study is to determine whether creative writing in newly diagnosed cancer patients and those with recent progression in their disease will have a positive impact on their mental health. Using a randomized controlled trial approach, emotion thermometers will be employed to evaluate participants' responses on a number of domains, such as anxiety, depression, despair, and anger along with a series of survey questions to monitor changes in depressive and anxiety symptoms. Open-ended survey questions will be used to capture how a creative writing intervention impacts participants' experience of their illness. Melissa Greene's Write from the Heart program focuses more on creative writing rather than cancer focused topics. Patients in the intervention arm will complete -one and a half hour group sessions every two weeks over the span of 3 months. Participants in the active control arm will be provided a book (i.e., Writing Down Bones by Natalie Goldberg) about creative writing and will be asked to do activities for 1.5 hrs every 2 weeks for a period of 3 months.
Status | Completed |
Enrollment | 60 |
Est. completion date | November 16, 2018 |
Est. primary completion date | November 16, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: Newly diagnosed with any stage or type of cancer within 3 months OR progression of disease within 3 months of enrollment. Recurrence of cancer within 3 months of enrollment would also be eligible as it will be considered as progression of cancer Ability to understand English language and ability to write without any functional difficulty ECOG performance status 0-3 Exclusion Criteria: Inability to give informed consent Severe psychiatry illness (e.g., uncontrolled depression, schizophrenia or psychosis) Severe cognitive impairment Pregnant females Inability to write or understand English |
Country | Name | City | State |
---|---|---|---|
United States | Penn State Cancer Institute | Hershey | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Milton S. Hershey Medical Center |
United States,
DOI: 10.1200/JCO.2017.35.31_suppl.178 Journal of Clinical Oncology 35, no. 31_suppl (November 2017) 178-178.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Status of Cancer at Consent | Comparison of status of cancer (stable, progressing, in remission) between intervention and control group. | consent | |
Other | Number of Subjects Who Were Admitted to the Hospital and ER Admissions During Study Time | Difference in number of emergency room visits and hospitalizations during study period between control and intervention group | 4 months | |
Other | Number of Subject That Were Not Hospital or ER Admissions After Study | Difference in number of emergency room visits and hospitalizations during study period between control and intervention group | 4 months | |
Other | Number of Emergency Room Visits and Hospitalizations Per Subject | Difference in number of emergency room visits and hospitalizations per subject during study period between control and intervention group | 4 months | |
Other | Status of Cancer at End of Study | Comparison of status of cancer (stable, progressing, in remission) between intervention and control group. | 4 months | |
Other | Number of Subject That Were Not Hospitalized or in the Emergency Room During Study Time | Difference in number of emergency room visits and hospitalizations by subject during study period between control and intervention group | 4 months | |
Primary | Emotional Thermometer Subscale 1- Distress at Final | Mood scores before and after intervention (after completion of entire session this may vary as some patients may not be able to complete six sessions). A validated Emotional Thermometer Scales (ETS) will be used to predict changes pre and post-intervention. The validated ETS has five dimensions (distress, anxiety, depression,anger, need help), which are all continuous variables and range from 0 to 10 with 0 being no emotional symptoms and 10 extremely emotional. Individual scores will be analyzed as well as a sum of the five scores will be collected to represent average mood score. | 4 months | |
Primary | Emotional Thermometer Subscale 2 - Anxiety at Final | Mood scores before and after intervention (after completion of entire session this may vary as some patients may not be able to complete six sessions). A validated Emotional Thermometer Scales (ETS) will be used to predict changes pre and post-intervention. The validated ETS has five dimensions (distress, anxiety, depression,anger, need help), which are all continuous variables and range from 0 to 10 with 0 being no emotional symptoms and 10 extremely emotional. Individual scores will be analyzed as well as a sum of the five scores will be collected to represent average mood score. | 4 months | |
Primary | Emotional Thermometer Subscale 3 - Depression at Final | Mood scores before and after intervention (after completion of entire session this may vary as some patients may not be able to complete six sessions). A validated Emotional Thermometer Scales (ETS) will be used to predict changes pre and post-intervention. The validated ETS has five dimensions (distress, anxiety, depression,anger, need help), which are all continuous variables and range from 0 to 10 with 0 being no emotional symptoms and 10 extremely emotional. Individual scores will be analyzed as well as a sum of the five scores will be collected to represent average mood score.re. | 4 months | |
Primary | Emotional Thermometer Subscale 4-anger at Final | Mood scores before and after intervention (after completion of entire session this may vary as some patients may not be able to complete six sessions). A validated Emotional Thermometer Scales (ETS) will be used to predict changes pre and post-intervention. The validated ETS has five dimensions (distress, anxiety, depression,anger, need help), which are all continuous variables and range from 0 to 10 with 0 being no emotional symptoms and 10 extremely emotional. Individual scores will be analyzed as well as a sum of the five scores will be collected to represent average mood score.. | 4 months | |
Primary | Emotional Thermometer Subscale 5-need Help at Final | Mood scores before and after intervention (after completion of entire session this may vary as some patients may not be able to complete six sessions). A validated Emotional Thermometer Scales (ETS) will be used to predict changes pre and post-intervention. The validated ETS has five dimensions (distress, anxiety, depression,anger, need help), which are all continuous variables and range from 0 to 10 with 0 being no emotional symptoms and 10 extremely emotional. Individual scores will be analyzed as well as a sum of the five scores will be collected to represent average mood score. | 4 months | |
Primary | Emotional Thermometer Score (Total) at Final | Mood scores before and after intervention (after completion of entire session this may vary as some patients may not be able to complete six sessions). A validated Emotional Thermometer Scales (ETS) will be used to predict changes pre and post-intervention. The validated ETS has five dimensions (distress, anxiety, depression,anger, need help), which are all continuous variables and range from 0 to 10 with 0 being no emotional symptoms and 10 extremely emotional. Individual scores will be analyzed as well as a sum of the five scores will be collected to represent average mood score.score. | 4 months | |
Secondary | Depression Symptoms | Severity of depression symptoms before and after intervention between two groups. The validated depression questionnaire, the Patient Health Questionnaire-9 (PHQ-9), will be used to predict changes. This questionnaire includes 9 questions, that describes individual symptoms of depression and asks individuals to asses how much each depression symptoms has bothered them in the last two weeks, from 0 (not at all) to 3 (nearly every day). The total score is compiled to represent a final depression severity score, with higher scores indicating worse severity, at a maximum value of 27 points. | 4 months | |
Secondary | Anxiety Symptoms | Severity of anxiety symptoms before and after intervention between two groups. The validated anxiety questionnaire, the Generalized Anxiety Disorder - 7 Scale, will be used to predict changes. This includes 7 questions describing symptoms of generalized anxiety, asking individual patients to rate how much those symptoms have bothered the individual in the past two weeks, from a score of 0 (not at all) to 3 (nearly every day). The total of the scores will be used to represent anxiety symptoms score, with a minimum score of 0 and a maximum score of 21, with higher score representing increasing severity of anxiety. | 4 months | |
Secondary | Self Reported Somatic Symptoms at Final | Self-reported somatic symptoms pre and post intervention in two groups. We will use the Somatic Symptom Scale - 8 (SSS-8) to quantify somatic symptom burden. The scale is composed of 8 questions with options to choose a score of 0 (not at all) - 4 (very much) to describe degree of distress caused by individual somatic symptoms. A total of the 8 scores is used as a final value for the SSS-8, with higher scores indicating worse Somatic Symptom severity. | 4 months | |
Secondary | Depression Symptoms at Final | Severity of depression symptoms before and after intervention between two groups. The validated depression questionnaire, the Patient Health Questionnaire-9 (PHQ-9), will be used to predict changes. This questionnaire includes 9 questions, that describes individual symptoms of depression and asks individuals to asses how much each depression symptoms has bothered them in the last two weeks, from 0 (not at all) to 3 (nearly every day). The total score is compiled to represent a final depression severity score, with higher scores indicating worse severity, at a maximum value of 27 points | 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03707548 -
BPT to Improve Bodily Disturbances in Post-treatment Cancer Patients
|
N/A | |
Not yet recruiting |
NCT06463782 -
Clinical Study of 68Ga-LNC1007 Injection PET/CT
|
Phase 1 | |
Not yet recruiting |
NCT04493450 -
NEMO - an App for Side Effect Management in Oncology
|
||
Completed |
NCT05604820 -
The Effect of Progressive Muscle Relaxation Exercise on Sleep Quality
|
N/A | |
Completed |
NCT04024748 -
Verification of Imaging System PCD-1000A
|
||
Completed |
NCT03320161 -
A Patient Consensus for the Research in Supportive Care in French Cancer Care Centers: the CyPRES Project
|
||
Recruiting |
NCT05547282 -
Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure
|
N/A | |
Recruiting |
NCT01742143 -
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
|
||
Completed |
NCT05368116 -
Effectiveness of Video Assisted Self Management Program on Chemotherapy Related Side Effects .
|
N/A | |
Recruiting |
NCT01603316 -
Food: A Three-Arm Study Examining Food Insecurity Interventions
|
Phase 2 | |
Recruiting |
NCT03100071 -
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients
|
||
Completed |
NCT04037410 -
Environmental Temperature and White Adipose Tissue in Cancer Patients
|
||
Recruiting |
NCT06305741 -
A Study of an Anxiety Intervention for Latino/Latina/Hispanic Older Adults With Cancer and Their Caregivers
|
N/A | |
Recruiting |
NCT05279378 -
Correlation of Lung Ultrasonography With Chest CT Findings in Cancer Patients With COVID-19 Viral Pneumonia
|
||
Not yet recruiting |
NCT05922423 -
Exploration of Management Model and Intervention Research on Fear of Cancer Recurrence
|
N/A | |
Completed |
NCT01704469 -
A Comparison of the Perception of a Needle Injection Pain Between Cancer Patients Receiving Opioid Therapy Versus Opioid-naive Patients
|
N/A | |
Active, not recruiting |
NCT06348940 -
Effects of Behavioral Activation on Negative Emotions, Cancer-related Symptoms and Clinical Indicators in Cancer Patients
|
N/A | |
Completed |
NCT04302792 -
New Food Solutions for Cancer Patients
|
N/A | |
Recruiting |
NCT05219851 -
The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
|
||
Completed |
NCT05884047 -
The Effect Of Virtual Reality Glasses On Vital Signs And State Anxiety Level In Cancer Patients
|
N/A |